The results of the Panku-Breast01 phase III clinical study for later treatment of HR+HER2 advanced breast cancer, independently developed by Baili Tianheng, were announced during the major Late-Breaking Abstract session of the conference. The research results were simultaneously listed in the main issue of “The Lancet” and published in full.

The results of the Panku-Breast01 phase III clinical study for later treatment of HR+HER2 advanced breast cancer, independently developed by Baili Tianheng, were announced during the major Late-Breaking Abstract session of the conference. The research results were simultaneously listed in the main issue of “The Lancet” and published in full.